Skip to content

New Industries Require New Insight 

The microbiome and its role in human health represents a paradigm shift in how medicines will be developed. The PRI was founded to make Microbiotic Medicinal Products a therapeutic reality in Europe.

A Unique Collaborative Approach

The PRI, as a neutral and financially independent non-profit association, applies a unique collaborative approach to improve market access and provide technical and regulatory intelligence for its members.

The Future of Human Health

The PRI believes that the microbiome is the future of human medicine. Our members have a stake in regulatory, technical and collaboration efforts of the microbiome & human health space. 

Board Members 

President

Bruno Pot

Yakult Europe

First Vice President

Sandrine Claus

YSOPIA Bioscience

Second Vice President

Charlotte Hemmingsen

Chr. Hansen

Secretary

Frédérique Vieville

5QBD Biotech

Treasurer

Stanislas Desjonquères

Nexbiome Therapeutics

Board Member

Jelena Cvejic

Accelsiors CRO

Ana Enriquez

ADM Protexin

Nail Nasir

Astel Medica

Vincent Thomas

Bioaster

Gianfranco Grompone

BioGaia AB

Luc Sterkman

Caelus Health

Anette Gemal

Ferring Pharmaceuticals

Board Members 

Katarina Lundh

Johnson & Johnson

Eric Clarke

Labskin UK

Sylvie Binda

Lallemand Health Solutions

Eugenio Fernandez

MaaT Pharma

Selin Bolca

MRM Health
POSTECH

Sin-Hyeog Im

POSTECH

Marco Pane

Probiotical

Grégory Lambert

TargEDys

Monique Alric

University Clermont-Auvergne (UCA)

Laurent Rios

VetAgro Sup

Ingmar Claes

YUN Probiotherapy

Meet the Team

Magali

Scientific & Regulatory Affairs Director

Céline

Microbiome Project Manager

Joseph

Operations Manager

Nick

Pharmabiotics Event Director

Our Members

Start Ups

Start Ups

Biotechs

Biotechs

Investors

Investors

CROs

Research Institutions

LBP Developers

LBP Developers

CDMOs

CDMOs

Pharma

Membership in the PRI plays an important role in several of our members’ development & marketing strategies. 

Intelligence

Development Planning

Networking

Scientific Foresight

Investment

What are Microbiotic Medicinal Products (MMPs)?

The PRI defines MMPs as any medicinal product containing living, dead or fragments…, of components of the microbiome (i.e. bacteria, yeasts, phages, etc…) with the purpose to prevent or treat human diseases through a pharmacological, microbiological, neurological, immunological or metabolic mode of action, or make a medical diagnosis.

Non-Living Cells

Non-Living Cells

Live Biotherapeutic Products

Live Biotherapeutic Products

Faeces-derived Rx

Faeces-derived Rx

Phage Therapy

Phage Therapy

The PRI is Europe’s leading Microbiome Regulatory Expertise Center dedicated to supporting the development of microbiome-based medicines for the EU Market.

Expertise

Patients/Health

Medicine

Synergy

Find out more about the PRI from some of her members…

One-to-One Partnering

Microbiome dedicated one-to-one partnering forum. Schedule 20+ meetings with decision makers from Academia & Industry.

Conference

30+ presentations covering topics such as Cancer, Gut-Lung Axis, Urogenital as well as Regulatory Affairs and Market Trends.

Exhibition

Tailor suited solutions for your business needs. Promote your products and services to the Global Microbiome Community.

Innovation Showcase

Start-ups, spin-offs, academics & entrepreneurs present the latest innovations of microbiome products, services and research.

Contact Us

Our team is available to answer any questions you may have. Please contact us by phone or email us directly. 

Send us a message: